|B7-H3 (also known as CD276) is an immune checkpoint receptor that plays an important role in cancer cell migration, invasion, and proliferation.
Location: Chromosome 15q24.2
B7-H3 is a member of the B7/CD28 superfamily of immune checkpoint molecules. Overexpression of B7-H3 in numerous cancer types has been shown to be correlated with advanced tumor stage and high tumor grade. B7-H3 has possible roles in regulating cancer metabolism, protein regulation, cell proliferation, and epithelial-mesenchymal transition.
B7-H3 in Chordoma
- B7-H3 (CD276 antigen) is key component of cell migration and proliferation. Expression of B7-H3 could be a useful prognostic biomarker in chordoma. As B7-H3 is expressed on the cell-surface and is unregulated on tumor compared to normal cells, it also represents an attractive candidate for targeting by antibody immunotherapy in bone cancers.1
- Molecular Evidence
- 58/70 (83%) chordoma cases were positive for B7-H3 expression by immunohistochemistry. 1 of 6 notochord controls stained positively for B7-H3.2
- Protein expression of B7-H3 was not associated with metastasis or survival but had some association with local recurrence3 and lack of expression of B7-H3 was suggestive of a benign course.2